

## Pharmacy Policy

### Metabolic Bone Disease Agents

Policy Number: 9.318

Version Number: 1

Version Effective Date: 1/1/2021

#### Product Applicability All Plan+ Products

##### Well Sense Health Plan

New Hampshire Medicaid

##### Boston Medical Center HealthNet Plan

MassHealth - MCO

MassHealth - ACO

Qualified Health Plans/ConnectorCare/Employer Choice Direct

Senior Care Options

Note: Disclaimer and audit information is located at the end of this document.

## Prior Authorization Policy

#### Products Affected:

- **Evenity (romosozumab-aqqg)**
- **Prolia (denosumab)**
- **Tymlos (abaloparatide)**
- **Xgeva (denosumab)**

The Plan may authorize coverage of the above products for members meeting the following criteria:

<b>Covered Use</b>	All FDA approved indications not otherwise excluded
<b>Exclusion Criteria</b>	Evenity: member has had a stroke or MI within the previous year
<b>Required Medical Information</b>	<p><b>Prolia</b></p> <ol style="list-style-type: none"> <li>1. One of the diagnoses:                     <ol style="list-style-type: none"> <li>a. postmenopausal osteoporosis</li> <li>b. osteoporosis in men</li> <li>c. non-metastatic breast cancer receiving adjuvant aromatase inhibitor therapy</li> <li>d. non-metastatic prostate cancer receiving androgen deprivation therapy</li> <li>e. glucocorticoid-induced osteoporosis; AND</li> </ol> </li> </ol>

\* Plan refers to Boston Medical Center Health Plan, Inc. and its affiliates and subsidiaries offering health coverage plans to enrolled members. The Plan operates in Massachusetts under the trade name Boston Medical Center HealthNet Plan and in other states under the trade name Well Sense Health Plan.

	<ol style="list-style-type: none"> <li>2. T-score is less than or equal to -2.5 as evidenced via a DXA bone density scan or T-score is between -1.0 and -2.5 as evidenced via a DXA bone density scan and multiple risk factors for fractures (must document risk factors*); AND</li> <li>3. An inadequate response (defined as a declining T-score from baseline or a fragility fracture) or intolerance to a trial of at least one oral bisphosphonate; or contraindication (i.e., esophageal stricture, achalasia, etc) to oral bisphosphonates; AND</li> <li>4. An inadequate response (defined as a declining T-score from baseline or a fragility fracture) or intolerance to a trial of one injectable bisphosphonate; or contraindication to injectable bisphosphonates</li> </ol> <p><b><u>Tymlos, Evenity</u></b></p> <ol style="list-style-type: none"> <li>1. A diagnosis of post-menopausal osteoporosis; AND</li> <li>2. T-score is less than or equal to -2.5 as evidenced via a DXA bone density scan or T-score is between -1.0 and -2.5 as evidenced via a DXA bone density scan and multiple risk factors for fractures (must document risk factors*); AND</li> <li>3. An inadequate response (defined as a declining T-score from baseline or a fragility fracture) or intolerance to one oral bisphosphonate; or contraindication (i.e., esophageal stricture, achalasia, etc) to oral bisphosphonates; AND</li> <li>4. An inadequate response (defined as a declining T-score from baseline or a fragility fracture) or intolerance to one injectable bisphosphonate; or contraindication to injectable bisphosphonates</li> <li>5. An inadequate response, intolerance or contraindication to trial of Prolia</li> </ol> <p><b><u>Xgeva</u></b></p> <ol style="list-style-type: none"> <li>1. Diagnosis of multiple myeloma or solid tumor with bone metastases; OR</li> <li>2. Diagnosis of giant cell tumor of the bone; AND The tumor is unresectable or surgical resection is likely to result in severe morbidity; OR</li> <li>3. Diagnosis of hypercalcemia of malignancy; AND An intolerance, contraindication, or treatment failure to a trial of zoledronic acid (Zometa)</li> </ol>
<b>Age Restriction</b>	None
<b>Prescriber Restriction</b>	Evenity: prescribed by or in consultation with an endocrinologist
<b>Coverage Duration</b>	Evenity: 12 months Tymlos, Prolia, Xgeva: 24 months
<b>Other criteria</b>	Continuation of therapy is clinically appropriate and does not exceed lifetime limit.

*\*Risk factors for fracture include advanced age, prior history of fragility fracture, chronic glucocorticoid use, low BMI, parental history of hip fracture, family history of osteoporosis, cigarette smoking, excess alcohol consumption, and presence of medical diseases that are associated with low BMD, such as rheumatoid arthritis, inflammatory bowel disease, type 1 diabetes, chronic liver disease.*

*\*\*Zometa® (zoledronic acid IV soln 4 mg) is covered without a PA*

## Appendix A – Applicable HCPCs

Code	Medication
------	------------

<sup>\*</sup> Plan refers to Boston Medical Center Health Plan, Inc. and its affiliates and subsidiaries offering health coverage plans to enrolled members. The Plan operates in Massachusetts under the trade name Boston Medical Center HealthNet Plan and in other states under the trade name Well Sense Health Plan.

Code	Medication
J0897	denosumab injection (Xgeva or Prolia)
J3111	Romosozumab injection (Evenity)

## Clinical Background Information and References

---

Original Approval Date	Original Effective Date	Policy Owner	Approved by
12/1/2020	1/1/2021	Pharmacy Services	Pharmacy & Therapeutics (P&T) Committee

Policy Revisions History			
Review Date	Summary of Revisions	Revision Effective Date	Approved by
12/1/2020	9.099 Metabolic Bone Disease Agents Policy retired, new policy created	1/1/2021	P&T Committee

## Next Review Date

---

2021

## Other Applicable Policies

---

## Reference to Applicable Laws and Regulations, If Any

---

### Disclaimer Information

Medical Policies are the Plan's guidelines for determining the medical necessity of certain services or supplies for purposes of determining coverage. These Policies may also describe when a service or supply is considered experimental or investigational, or cosmetic. In making coverage decisions, the Plan uses these guidelines and other Plan Policies, as well as the Member's benefit document, and when appropriate, coordinates with the Member's health care Providers to consider the individual Member's health care needs.

Plan Policies are developed in accordance with applicable state and federal laws and regulations, and accrediting organization standards (including NCQA). Medical Policies are also developed, as appropriate, with consideration of the medical necessity definitions in various Plan products, review of current literature, consultation with practicing Providers in the Plan's service area who are medical experts in the particular field, and adherence to FDA and other government agency policies. Applicable state or federal mandates, as well as the Member's benefit document, take precedence over these guidelines. Policies are reviewed and updated on an annual basis, or more frequently as needed. Treating providers are solely responsible for the medical advice and treatment of Members.

\* Plan refers to Boston Medical Center Health Plan, Inc. and its affiliates and subsidiaries offering health coverage plans to enrolled members. The Plan operates in Massachusetts under the trade name Boston Medical Center HealthNet Plan and in other states under the trade name Well Sense Health Plan.

The use of this Policy is neither a guarantee of payment nor a final prediction of how a specific claim(s) will be adjudicated. Reimbursement is based on many factors, including member eligibility and benefits on the date of service; medical necessity; utilization management guidelines (when applicable); coordination of benefits; adherence with applicable Plan policies and procedures; clinical coding criteria; claim editing logic; and the applicable Plan – Provider agreement.

<sup>†</sup> *Plan* refers to Boston Medical Center Health Plan, Inc. and its affiliates and subsidiaries offering health coverage plans to enrolled members. The Plan operates in Massachusetts under the trade name Boston Medical Center HealthNet Plan and in other states under the trade name Well Sense Health Plan.